CL2018002677A1 -
Pharmaceutical composition comprising a) metformin, b) rosiglitazone or pioglitazone, c) sitagliptin, linagliptin or vildagliptin, and excipients; and its use for the treatment of the development of ehna, insulin resistance syndrome and type 2 diabetes mellitus, sop.
- Google Patents
Pharmaceutical composition comprising a) metformin, b) rosiglitazone or pioglitazone, c) sitagliptin, linagliptin or vildagliptin, and excipients; and its use for the treatment of the development of ehna, insulin resistance syndrome and type 2 diabetes mellitus, sop.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cordova Ortega Sebastian IgnaciofiledCriticalCordova Ortega Sebastian Ignacio
Priority to CL2018002677ApriorityCriticalpatent/CL2018002677A1/en
Publication of CL2018002677A1publicationCriticalpatent/CL2018002677A1/en
COMPOSICIÓN FARMACÉUTICA QUE COMPRENDE A) 500 A 1000MG METFORMINA, B) 0,5 A 0,9MG ROSIGLITAZONA O 5 A 10 MG PIOGLITAZONA, C) 10 A 40MG SITAGLIPTINA, 0,625 A 2MG LINAGLIPTINA O 10 A 40MG VILDAGLIPTINA, Y EXCIPIENTES; Y SU USO PARA EL TRATAMIENTO DEL DESARROLLO DE HIGADO GRASO NO ALCOHÓLICO, SINDROME DE INSULINO-RESISTENCIA Y LA DIABETES MELLITUS TIPO 2, SINDROME DE OVARIO POLIQUISTICOPHARMACEUTICAL COMPOSITION INCLUDING A) 500 TO 1000MG METFORMIN, B) 0.5 TO 0.9MG ROSIGLITAZONE OR 5 TO 10 MG PIOGLITAZONA, C) 10 TO 40MG SITAGLIPTINE, 0.625 TO 2MG LINAGLIPTINE OR 10 TO 40MG VILDAGLIPTIN, AND AND ITS USE FOR THE TREATMENT OF THE DEVELOPMENT OF NON-ALCOHOLIC FAT LIVER, INSULIN-RESISTANCE SYNDROME AND MELLITUS TYPE 2 DIABETES, POLYCHISTIC OVARY SYNDROME
CL2018002677A2018-09-212018-09-21
Pharmaceutical composition comprising a) metformin, b) rosiglitazone or pioglitazone, c) sitagliptin, linagliptin or vildagliptin, and excipients; and its use for the treatment of the development of ehna, insulin resistance syndrome and type 2 diabetes mellitus, sop.
CL2018002677A1
(en)
Pharmaceutical composition comprising a) metformin, b) rosiglitazone or pioglitazone, c) sitagliptin, linagliptin or vildagliptin, and excipients; and its use for the treatment of the development of ehna, insulin resistance syndrome and type 2 diabetes mellitus, sop.
Pharmaceutical composition comprising a) metformin, b) rosiglitazone or pioglitazone, c) sitagliptin, linagliptin or vildagliptin, and excipients; and its use for the treatment of the development of ehna, insulin resistance syndrome and type 2 diabetes mellitus, sop.
Pharmaceutical composition comprising a) metformin, b) rosiglitazone or pioglitazone, c) sitagliptin, linagliptin or vildagliptin, and excipients; and its use for the treatment of the development of ehna, insulin resistance syndrome and type 2 diabetes mellitus, sop.
Composed of pegylated insulin lispro or a salt thereof comprising a chain a of sec no: 1, a chain b of sec no: 3 and the peg is of a weight between 20 to 40 kda; use of said compound to treat hypoglycemia or diabetes; pharmaceutical composition comprising said compound; and process for making said compound.
Imidazo [2,1-b] -thiazole derived compounds; pharmaceutical composition comprising said compound; and use of the compound for the treatment of diabetes, metabolic syndrome, insulin resistance, among others.
COMPOUNDS DERIVED FROM PIRIMIDO- [4,5-B] -OXAZINAS; PREPARATION PROCEDURE; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUND; AND USE OF THE COMPOUND IN THE TREATMENT OF MELLITUS DIABETES AND / OR OBESITY.
ALISQUERENO SALT; PREPARATION PROCEDURE; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH SALT; AND USE OF THE COMPOUND FOR THE TREATMENT OF DISEASES THAT CAN BE MODULATED BY THE INHIBITION OF THE RHENINE.
INHIBITOR OF THE CHOLESTERILE ESTER TRANSFER PROTEIN (CETP) AND PHARMACEUTICAL COMPOSITIONS THAT INCLUDE SUCH INHIBITOR FOR USE IN THE TREATMENT OR PREVENTION OF CARDIOVASCULAR DISEASES
Pharmaceutical composition comprising a) metformin, b) rosiglitazone or pioglitazone, c) sitagliptin, linagliptin or vildagliptin, and excipients; and its use for the treatment of the development of ehna, insulin resistance syndrome and type 2 diabetes mellitus, sop.
Pharmaceutical composition for the prevention or treatment of cardiovascular diseases accompanied by diabetes, including amlodipine, losartan and rosuvastatin, and compound preparation including the same